William T. Carpenter, Jr., M.D.

Name, Degree:  William Carpenter, Jr., M.D.
Role(s) in Work Group:  Chair, Psychotic Disorders Work Group
Institutional Affiliation(s):  University of Maryland School of Medicine
City, State:  Baltimore, MD

Biographical Sketch:
William T. Carpenter, Jr., M.D.
Director, Maryland Psychiatric Research Center
Professor of Psychiatry and Pharmacology
University of Maryland School of Medicine
Baltimore, Maryland

William T. Carpenter, Jr., M.D., is a Professor of the University of Maryland School of Medicine and the Director of the Maryland Psychiatric Research Center. He obtained his medical degree from the Wake Forest University School of Medicine. After an internship at the North Carolina Baptist Hospital, he undertook postgraduate training at the University of Rochester Medical Center. He began his research career with the National Institute of Mental Health Intramural Program in 1966, using neuroendocrine strategies to study the psychobiology of affective disorders. He has also been a collaborating investigator with the World Health Organization’s International Pilot Study of Schizophrenia.  Dr. Carpenter is the Editor-in-Chief for Schizophrenia Bulletin and has served on the editorial boards of the Archives of General Psychiatry, Biological Psychiatry, the Journal of Nervous and Mental Disease, Neuropsychopharmacology, Psychiatry Research, Schizophrenia Bulletin, Schizophrenia Research, Current Psychiatry Reports, and the CD-ROM version of the American College of Neuropsychopharmacology publication Neuropsychopharmacology: Fourth Generation of Progress, and has authored over 300 publications.  Dr. Carpenter is Past-President of the American College of Neuropsychopharmacology and participated in the founding of the National Alliance for Research on Schizophrenia and Depression (NARSAD) and chairs the scientific program committee.

Dr. Carpenter’s major professional interest has been severe mental illness, especially schizophrenia, including phenomenology of the psychoses, the etiology, pathophysiology, anatomy, and treatment of schizophrenia. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of new treatments, and research ethics. His special professional assignments include service on the NIMH Intramural Research Program Board of Scientific Counselors and as a consultant and reviewer for NIMH and National Institutes of Health on many topics. He chaired the NIMH Research Scientist Career Development Committee and the NIMH National Plan Committee on Treatment Research. Dr. Carpenter has served as Principle Investigator on an NIMH-funded Clinical Research Center (now Advanced Centers for Interventions and Services Research) and an NIMH-funded Center for Neuroscience and Schizophrenia. He provided expert testimony in the cases of the United States Government v. John Hinckley and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He has been the recipient of national and international research awards. Dr. Carpenter was elected to the Institute of Medicine of the National Academy of Sciences in 1998.

Non-Profit and Advocacy Organizations

Year(s)

Role

NARSAD                                                                                               

2003-2008

Scientific Council

ACNP

2003-2008

Fellow, Elected Official

NAMI

2003-2008

Member, Scientific Council


KEY NUMBER:
1. Consultation Fees  (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options 

6. Expert testimony
7.  Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10.  Other  (specify)

Disclosure of significant interests for 2005, 2006, and 2007 

Commercial or Other Organization

Year(s)

Key #(s)

Astra Zeneca                                                                       

2004, 2006

1

Atrix Laboratories

2004

1

Bristol-Myers Squibb                                                         

2003

1

Centron (Solvay/Wyeth)

2007

1

Cephalon

2007

1

Janssen

2003-2006

1

Johnson & Johnson                                                           

2005

1

Lilly                                                                                        

2004, 2006

1

McNeil                                                                                  

2006

1

Merck                                                                                   

2006

1

Pfizer                                                                                     

2005-2006

1, 4

Pro Neura Technology                                                                     

2004

1

Saatchi & Saatchi                                                                              

2004

1

Solvay/Wyeth                                                                       

2004-2007

1

European Regional Patent Number 1487998 (June 6, 2007)  “Methods for Diagnosing and Treating Schizophrenia”

2007

8


Disclosure of significant interests to date for 2008 and commitments for remainder of year

Commercial or Other Organization

Year(s)

 

Key #(s)

Centron (Solvay/Wyeth)                                                     

2008

1

Cephalon                                                                             

2008

1

Teva Pharmaceuticals                                                     

2008

1

European Regional Patent Number 1487998 (June 6, 2007)  “Methods for Diagnosing and Treating Schizophrenia”

2008

8

From: 
Email:  
To: 
Email:  
Subject: 
Message: